Key result
ANP T2238C and G1837A gene polymorphisms showed no significant association with essential hypertension risk (e.g., T2238C C vs. T: OR 1.1; 95% CI 0.94-1.2; p=0.38), though T1766C may be protective.
Why the study?
Are atrial natriuretic peptide (ANP) genetic polymorphisms associated with the risk of essential hypertension?
Population
10,730 individuals (5,520 cases of essential hypertension and 5,210 controls) from 25 case-control studies
Comparison
Presence of atrial natriuretic peptide genetic… vs Absence of these specific ANP genetic…
Design
Meta-analysis
Authors
Loading...
No association for T2238C/G1837A does not support ANP genotyping in hypertension risk assessment; leaves T1766C protective effect open for validation.
Meta-Analysis (n=10,730)
Are atrial natriuretic peptide (ANP) genetic polymorphisms associated with the risk of essential hypertension?
Odds Ratio: 1.1 (95% CI 0.94–1.2)
p-value: p=0.38
ANP T2238C and G1837A polymorphisms are not significantly associated with essential hypertension risk, whereas the T1766C polymorphism may offer a protective effect.
Wang et al. (2016) conducted a meta-analysis in essential hypertension (n=10,730). ANP genetic polymorphism (T2238C, G1837A, T1766C) vs. Reference alleles was evaluated on overall essential hypertension risk (T2238C C vs. T) (OR 1.1, 95% CI 0.94-1.2, p=0.38). ANP T2238C and G1837A gene polymorphisms showed no significant association with essential hypertension risk (e.g., T2238C C vs. T: OR 1.1; 95% CI 0.94-1.2; p=0.38), though T1766C may be protective.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: